Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
Study Details
Study Description
Brief Summary
To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of Essential Tremor.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
To compile characteristics of real-world outcomes using Deep Brain Stimulation (DBS) for the treatment of Essential Tremor to add to the evidence available for treatment of ET.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Essential Tremor Subjects with Essential Tremor being implanted with Boston Scientific Deep Brain Stimulation Systems |
Device: Deep Brain Stimulation Systems (DBS)
Subjects receiving DBS implant for treatment of Essential Tremor
|
Outcome Measures
Primary Outcome Measures
- Change in Quality of Life during the study as compared with baseline using the Quality of Life in Essential Tremor Questionnaire (QUEST) [Up to 3 years]
Change in quality of life over the course of the study using QUEST
Other Outcome Measures
- Change in tremor scores during the study as compared with baseline as assessed by Fahn-Tolosa- Marin Rating Scale [Up to 3 years]
Improvement in tremor scores as assessed by Fahn-Tolosa-Marin Tremor Rating Scale (FTMTRS) during the study as compared with baseline
- Impression of Change scores during the study using Global Impression of Change [Up to 3 years]
Impression of Change scores during the study using Global Impression of Change
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Meets criteria established in the locally applicable Directions for Use (DFU) for Essential Tremor
-
Is at least 18 years old
Exclusion Criteria:
- Meets any contraindication in locally applicable Directions for Use
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | AZ Sint-Lucas | Gent | Belgium | ||
2 | AZ Delta | Roeselare | Belgium | ||
3 | Uniklinik Koln | Cologne | Germany | ||
4 | Universitatsklinikum Campus Kiel | Kiel | Germany | ||
5 | Universitaetsklinikum Wuerzburg | Würzburg | Germany | ||
6 | Medical School of University PECS | Pécs | Hungary | ||
7 | Policlinico Universitario Agostino Gemelli | Rome | Italy | ||
8 | Samsung Medical Center | Seoul | Korea, Republic of | ||
9 | Seoul ASAN Medical Center | Seoul | Korea, Republic of | ||
10 | CHU Sao Joao | Porto | Portugal | ||
11 | Hospital De Bellvitge | Barcelona | Spain | 30326 | |
12 | Hospital General De Asturias | Oviedo | Spain |
Sponsors and Collaborators
- Boston Scientific Corporation
Investigators
- Study Director: Roshini Jain, Boston Scientific Corporation
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- A4080